Why the study?
To evaluate long-term prognosis and outcomes over 24 months in patients with tachycardia-induced cardiomyopathy.
Tachycardia-induced cardiomyopathy is a reversible cause of left ventricular dysfunction with significant LVEF improvement on therapy, though one-third of patients experience recurrence within 24 months.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Orlov et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: